Spine Biologics Market
The Spine Biologics Market Share is projected to grow from USD 2.9 Billion in 2023 to USD 4.3 Billion by 2032, exhibiting a CAGR of 4.90% during the forecast period (2023 – 2032).
Market Dynamics
The aging population, an increase in the frequency of spine deformities, and technological advancements in bone grafting technologies are driving the global market. Furthermore, rising rates of preference for less invasive procedures, as well as rising frequencies of degenerative spine diseases, are both boosting market growth. Furthermore, interbody fusion and direct lateral interbody fusion are the two cutting-edge biological procedures most commonly employed by surgeons around the world to address spinal abnormalities.
The global old population is growing, which will raise the demand for treatment and identification of disorders. People over the age of 50 are more likely to sustain a spinal injury due to structural changes in the spine or spinal abnormalities. During the forecast timeframe, the market for spine biologics will thus be driven by the aforementioned factors. The key factors driving the growth of the spine biologics market are an increase in degenerative spine diseases instances and a significant increase in treatment rates globally.
Because of technological advancements in bone grafting technologies, the importance of these biologics in spine surgery, and the increased desire for less invasive procedures, the market for spine biologics is rapidly expanding. The increased acceptance of biomaterials as a result of their rapid healing, short recovery times, and ability to stimulate cellular growth, as well as their widespread use in the treatment of degenerative disc disorders, spinal cord injuries, and bone fusion procedures, has had a significant impact on the spine biologics industry.
Spine Biologics Market Outlook and Research Report Information By Product (Bone Allografts, Bone Graft Substitute, Platelet Rich Plasma, And Bone Marrow Aspirate Therapy), By Surgery Type (Anterior Cervical Discectomy And Fusion (ACDF), Transforamenal Lumbar Interbody Fusion (TLIF), Anterior Lumbar Interbody Fusion (ALIF), and Lateral Lumbar Interbody Fusion (LLIF)), By End User (Hospitals, Spinal Surgery Centers, and Others), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032.
Major Key Players:
Some of the Spine Biologics Market Players are Arthrex, Inc., Cesca Therapeutics Inc., DePuy Synthes, Orthopaedic Seminar, Exactech, Inc., K2M, Inc., Lattice Biologics Ltd, Medtronic, NuTech Spine, Inc. NuVasive Inc., Orthofix Holdings, Inc., Regen Lab USA LLC, RTI Surgical Holdings, Inc., Stryker, Wright Medical Group N.V., XTANT MEDICAL, Zimmer Biomet, Smith & Nephew, Dr PRP USA LLC
Segment Analysis
The Spine Biologics Market segmentation, based on Product includes bone allografts, bone graft substitute, platelet rich plasma, and bone marrow aspirate therapy.
The Spine Biologics Market segmentation, based on Surgery Type, includes anterior cervical discectomy and fusion (ACDF), transforamenal lumbar interbody fusion (TLIF), anterior lumbar interbody fusion (ALIF), and lateral lumbar interbody fusion (LLIF).
The Spine Biologics Market segmentation, based on end user, includes hospitals, spinal surgery centers, and others.
Regional Analysis
North America has the largest market share (45.80%) for spine biologics worldwide. The rise in the prevalence of spine diseases such as spinal stenosis, disc-related difficulties, and spondylolisthesis, as well as steady economic growth, are all contributing reasons to the market's expansion. Furthermore, the United States had the biggest market share, while Canada had the fastest expanding market in North America.
The Europe Spine Biologics market is expected to expand at a rapid pace during the forecast period. Technological developments, an increase in hospitals, and an expanded patient base for spine biologics are driving market growth in this field. Furthermore, the German Spine Biologics market dominated, while the UK Spine Biologics market was the fastest expanding in the European region.
Due to a large patient population and increased awareness of the benefits of biologics among patients and surgeons, the Asia-Pacific Spine Biologics market is predicted to develop at the quickest CAGR from 2023 to 2032. Factors such as the region's improving infrastructure and healthcare facilities, rising healthcare expenses, and the high prevalence of spine injuries, particularly those caused by traffic accidents, are driving the regional market.
About Market Research Future
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 646 845 9312
Email: sales@marketresearchfuture.com
